Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:
FSE:4530'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.68 Med: 22.68 Max: 37.52
Current: 18.23
During the past years, Hisamitsu Pharmaceutical Co's highest Shiller PE Ratio was 37.52. The lowest was 17.68. And the median was 22.68.
FSE:4530's Shiller PE Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 25.54
vs FSE:4530: 18.23
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Hisamitsu Pharmaceutical Co's adjusted earnings per share data for the three months ended in Nov. 2025 was 円68.690. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is 円218.04 for the trailing ten years ended in Nov. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Hisamitsu Pharmaceutical Co (FSE:4530) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Hisamitsu Pharmaceutical Co Shiller PE Ratio Related Terms
Hisamitsu Pharmaceutical Co Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co Shiller PE Ratio Chart
FSE:4530 vs AMPH, ESPR, NIKA: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Shiller PE Ratio falls into.
Hisamitsu Pharmaceutical Co Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Shiller PE Ratio of 18.23 as of Sep. 08, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors. This is 20% below median its historical median of 22.68. Over the past decade, Hisamitsu Pharmaceutical Co's Shiller PE Ratio has ranged from 17.68 to 37.52.
Is Hisamitsu Pharmaceutical Co's Shiller PE Ratio too high?
Hisamitsu Pharmaceutical Co's current Shiller PE Ratio of 18.23 is 20% below median its 10-year median of 22.68. Over the past 10 years, this metric has ranged from a low of 17.68 to a high of 37.52. The Drug Manufacturers industry median Shiller PE Ratio is 25.54. Hisamitsu Pharmaceutical Co's value of 18.23 is 28.6% below this industry median. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Shiller PE Ratio compare to AMPH and ESPR?
Hisamitsu Pharmaceutical Co's Shiller PE Ratio of 18.23 can be compared against companies in the Drug Manufacturers industry. The industry median Shiller PE Ratio is 25.54. Hisamitsu Pharmaceutical Co's value of 18.23 is 28.6% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Shiller PE Ratio has ranged from 17.68 to 37.52 over the past decade. While the company's 10-year median is 22.68 vs. the industry median of 25.54, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.54, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Shiller PE Ratio of 18.23 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Shiller PE Ratio is 18.23, which is 20% below median its own 10-year median of 22.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Shiller PE Ratio of 18.23. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Shiller PE Ratio is 18.23, which is 20% below median its 10-year median of 22.68 and 28.6% below the Drug Manufacturers industry median of 25.54. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Shiller PE Ratio is 18.23 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Shiller PE Ratio: 18.23 (20% below median its 10-year median of 22.68)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 28.6% below the Drug Manufacturers median
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
